The Trial Talk podcast explores how our work at the UCL Innovative Clinical Trials Unit (formerly the MRC Clinical Trials Unit at UCL) is improving health in the UK and around the world. Through conversations with world leading experts, researchers, and patient representatives, we take listeners inside the studies we run. From clinical trials in cancer, infectious diseases, and neurodegenerative conditions to pioneering research on trial methodology, the podcast unpacks important results, explores how studies can be designed and delivered more efficiently, and shows how public involvement is helping to shape better, smarter clinical trials.
MRC CTU Podcasts
Claim This Podcastby MRC Clinical Trials Unit at UCL
26 episodes
Updated Weekly
Accepts GuestsHas SponsorsLocation 🇬🇧
Podcast Overview
The Trial Talk podcast explores how our work at the UCL Innovative Clinical Trials Unit (formerly the MRC Clinical Trials Unit at UCL) is improving health in the UK and around the world. Through conversations with world leading experts, researchers, and patient representatives, we take listeners inside the studies we run. From clinical trials in cancer, infectious diseases, and neurodegenerative conditions to pioneering research on trial methodology, the podcast unpacks important results, explores how studies can be designed and delivered more efficiently, and shows how public involvement is helping to shape better, smarter clinical trials.
Language
🇺🇲
Publishing Since
9/5/2017
2 verified contact emails on file for MRC CTU Podcasts
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
June 30, 2026
The ACORD collaboration: Innovative Clinical Trials for Neurodegenerative Diseases
ACORD is a pioneering collaboration that brings together experts from a wide range of disciplines to accelerate the development of treatments for neurodegenerative diseases. In this episode, we explore how ACORD works in practice, the innovative methodologies that underpin it, including the multi-arm, multi-stage trial design, and the opportunities it creates for researchers at different stages of their careers. We speak with James Carpenter, one of ACORD’s founders, and Ed Jabbari, an ACORD Fellow, about the vision behind the collaboration, its potential to transform clinical research in neurodegenerative diseases, and how it has shaped Ed’s career journey. Further information is available on the ACORD collaboration page at www.innovative-ctu.ucl.ac.uk/.
October 30, 2024
International Clinical Trials Methodology Conference 2024 roundup - early careers edition
At the start of October, lots of the Unit’s clinical trials methodology researchers travelled to Edinburgh, for the 7th International Clinical Trials Methodology Conference (ICTMC). ICTMC is the largest academic-led conference on clinical trials, bringing together trialists from across the globe to present their latest work in trials methodology. This year's conference featured a wide variety of workshops, talks and poster presentations from MRC Clinical Trials Unit researchers. In this latest episode of the Trial Talk podcast, four of the Unit’s early career researchers discuss the work they presented at ICTMC 2024. Gideon Darko Asamoah tells us how he will deliver a core outcome set for trials in severe malaria; Jingyi Xuan describes her project addressing intercurrent events in platform trials; Dongquan Bi discusses the effects of different cluster sizes in cluster trials; and finally, Kate Roberts explains how she aims to improve the wording around consent for accessing trial participants' healthcare records. For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk For more information and to access the transcript: https://bit.ly/4f9grVi As a listener, your opinion is very valuable to us. Please help us to improve the podcast in future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g More resources: • Developing a core outcome set for severe malaria trials poster: https://www.mrcctu.ucl.ac.uk/posters/identifying-a-comprehensive-long-list-of-outcomes-for-developing-a-core-outcome-set-for-severe-malaria-treatment-trials-a-systematic-review-and-inclusion-of-outcomes-important-to-patients-and-caregivers/ • Specifying estimands and estimators in trials with complex designs poster: https://www.mrcctu.ucl.ac.uk/posters/specifying-estimands-and-estimators-in-trials-with-complex-designs/ • Demystifying estimands in cluster-randomised trials paper in Statistical Methods in Medical Research: https://journals.sagepub.com/doi/10.1177/09622802241254197 • Estimands in cluster-randomised trials paper in International Journal of Epidemiology: https://academic.oup.com/ije/article/52/1/107/6644521 • Current practice around the use of estimands in cluster randomised trials, and the impact of informative cluster size on inference poster: https://www.mrcctu.ucl.ac.uk/posters/current-practice-around-the-use-of-estimands-in-cluster-randomised-trials-and-the-impacts-of-informative-cluster-size-on-inferences/ • ICTMC 2024 Poster 167 – A rap song (Lyrics by Dongquan Bi, beat by David Fitzgerald): https://youtu.be/s7qZ5TnOlWU?si=iXwfFfSAWwJ-fAmk • CrossWord poster: https://www.mrcctu.ucl.ac.uk/posters/crossword-consent-to-access-and-use-healthcare-systems-data-for-clinical-trials-a-review-of-current-language-in-participant-facing-materials/
February 5, 2024
Lessons from UKCTOCS, a large-scale trial in ovarian cancer screening
UKCTOCS (UK Collaborative Trial of Ovarian Cancer Screening) is one of the largest screening trials in ovarian cancer. More than 200,000 women from England, Wales and Northern Ireland took part in it, and it ran for almost two decades. Designing and running such a large and lengthy trial came with its own challenges. In this episode, Professor Usha Menon discusses the key challenges that UKCTOCS faced in its design, conduct an analysis, and how the team addressed them. Further information is available on the UKCTOCS website at https://ukctocs.mrcctu.ucl.ac.uk/ Listen to the episode about the UKCTOCS trial results at https://bit.ly/48pK94J For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk For more information and to access the transcript: https://bit.ly/45XRyWT As a listener, your opinion is very valuable to us. Please help us to improve the podcast in the future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g
26 total episodes available
Deep-dive analytics for MRC CTU Podcasts
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is MRC CTU Podcasts?
- How often does this podcast release new episodes?
This podcast updates weekly.
- Where can I listen to this podcast?
This podcast is available on 8 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Information about guest appearances is not available.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.